Key result
Intravenous administration of VCL significantly reduced the frequency of cyclic flow variations in stenosed, endothelium-injured coronary arteries in baboons (from 18 to 1 per hour, P<.002).
Why the study?
Does VCL reduce cyclic flow variations and platelet aggregation in nonhuman primates with stenosed, endothelium-injured coronary arteries?
Population
Anesthetized, open-chest baboons with stenosed, endothelium-injured coronary arteries (n=18)
Comparison
VCL administered intravenously as a bolus… vs Placebo infusion of normal saline
Design
Preclinical
Follow-up
90 minutes of infusion plus up to >3 hours observation
Authors
Loading...
VCL merits further preclinical testing in coronary thrombosis; leaves open any role in human ACS pending translational studies.
Does VCL reduce cyclic flow variations and platelet aggregation in nonhuman primates with stenosed, endothelium-injured coronary arteries?
p-value: p=<.002
VCL, an antagonist of the von Willebrand-glycoprotein Ib binding domain, effectively abolishes cyclic flow variations and reduces platelet aggregation in a nonhuman primate model of coronary stenosis.
McGhie et al. (1994) studied Stenosed, endothelium-injured coronary arteries (n=18). VCL (peptide fragment derived from human plasma von Willebrand factor-glycoprotein Ib binding domain) vs. Placebo infusion of normal saline was evaluated on Frequency of cyclic flow variations per hour (p=<.002). Intravenous administration of VCL significantly reduced the frequency of cyclic flow variations in stenosed, endothelium-injured coronary arteries in baboons (from 18 to 1 per hour, P<.002).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: